Company: WHWK
Filing Date: 2025-03-31
Form Type: S-3
Source: 0001193125-25-068942
Chunk: 17

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-31
Form: S-3
Chunk 17
---
 | Less than 1% |

| 1. | The number of shares of our common stock in the column “Number of Shares of Common Stock Being                                                   
 Offered” represents all of the shares of our common stock that a selling stockholder may offer and sell from time to time under this prospectus. |

| 2. | We do not know when or in what amounts a selling stockholder may offer Shares for sale. The selling                                                                                                                                                      
 stockholders might not sell any or might sell all of the shares offered by this prospectus. Because the selling stockholders may offer all or some of the Shares pursuant to this offering, and because, except as set forth elsewhere in this           
 prospectus, there are currently no agreements, arrangements or understandings with respect to the sale of any of the Shares, we cannot estimate the number of the Shares that will be held by the selling stockholders after completion of the offering. 
 However, for purposes of this table, we have assumed that, after completion of the offering, none of the shares covered by this prospectus will be held by the selling stockholders.                                                                     |

| 3. | Consists of (i) 7,110,000 shares of common stock issuable upon the exercise of                                                                                                                                  
 pre-funded warrants purchased by ABG V-SIV Limited, (ii) 2,070,000 shares of common stock purchased in the Private Placement by ABG                                                                             
 V-SIV Limited , and (iii) 26,666 shares of common stock previously held by ABG Innovation-SO Limited. The pre-funded warrants may                                                                               
 not be exercised to the extent such exercise would cause ABG V-SIV Limited, together with its affiliates, to beneficially own in excess of 9.99% of the number of shares of our common stock outstanding        
 immediately after giving effect to such exercise. The beneficial ownership amounts in the table above do not give effect to this Beneficial Ownership Limitation solely for illustrative purposes. ABG V-SIV    
 Limited is wholly owned by Ally Bridge Group Global Life Science Capital Partners V, L.P. (“ABG V LP”) and ABG Innovation-SO Limited is wholly owned by Ally Bridge Group Innovation Capital                    
 Partners III, L.P. (the “ABG Fund”). Mr. Fan Yu is the controlling person of ABG Management Ltd. (“ABG Management”), the general partner of ABG V LP and ABG Fund and, in such capacity, has voting control and 
 investment control with respect to the shares